This one's frustrating - I can't actually find the preprint, just the press release, so perhaps the preprint will answer some questions. It's claiming a 12-week delay of BNT-Pfizer is better than the 3-week prescribed interval. Several problems...1/n
...It's signs of immune response in a small group of people: 99 had the 3-week interval, 73 had the 12-week interval. 3 problems in that: small number, immune response not health outcome, & no mention of how the differences in the people were taken into account ...2/n
...Why is that a problem? Because we need to know whether who was the highest priority for the vax contributed to the observed results - the 3-week interval is how the rollout started the vax first. For example, ...3/4
..they excluded 15 people who had a previous infection - 10 in the 3-week interval group. Could be coincidence in numbers this small. But I'm reserving judgment till it's possible to understand these 2 groups of people better. Plus, we really need health outcome data now. 4/4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Latest results for test-negative case-control study of Covid vax in US healthcare workers - & they get frequent testing.
March 18 data: 623 tested positive (cases) & 1,220 tested negative (controls). About a quarter Moderna vax, BNT-Pfizer the rest ...1/n cdc.gov/mmwr/volumes/7…
...Most of these healthcare professionals (HCPs) who got tested for Covid-19 were in roles that have substantial patient contact, most were aged 19-49, female, non-Hispanic white, underlying conditions that put them at risk if they got Covid-19 ...3/n
They've registered Sputnik Light in Russia, again on very thin data, again not waiting for phase 3. It's not a new vaccine: it's the 1st half of Sputnik V - an adenovirus 26 shot. Given the production problems since early on with the other half (Ad5)...1/n sputnikvaccine.com/newsroom/press…
...it's not surprising. (The Ad5 shot is the one there was a lot of controversy about recently because of replication-competence.) So it becomes a single-shot adenovirus vax (like J&J's & CanSino's) & it's half the price: full Sputnik V was expensive for Covid vax...2/n
...The data basis? 3 things: Immunogenicity results of a phase 1/2 trial with 110 people - some outcomes summarized in the press release only. Here's the trial register entry for it...3/n clinicaltrials.gov/ct2/show/NCT04…
Results of an analysis of adverse events after Sputnik V vax in San Marino. From those vaccinated early, so some healthcare workers & mostly older people. Median age 68, so a much lower rate would be expected than for a general population ...1/n (Preprint) medrxiv.org/content/10.110…
...Everyone who got vaccinated was invited to participate, but it appears to have had a very low response rate: eg 1,946 out of 8,799 aged 60-89 did (22%): nothing reported to gauge how similar they were to those who didn't. Total group is 2,588, of whom 1,288 had both shots..2/n
...People were contacted 7 days after vaccination, then at 1 month & 3 months. So there would be more recall bias than in a trial with a diary method, but less recall bias at 7 days than for later data...3/n
Oh my! Detail on adverse events in the Novavax UK trial included in a conference presentation - wish the numbers were there: definitely less than Moderna. Will need to blow this up & try to work it out! ...1/n novavax.com/sites/default/… HT @londonboyjohn
...A reminder of the vaccine efficacy rates for the phase 3 trial in the UK & the 2b efficacy trial in South Africa. It's an adjuvanted protein subunit vaccine...2/n
...They've made a booster aiming at the B.1.351 variant of concern. Here you see responses in baboons that had been immunized with the original a year ago. Bonus: you see with & without their adjuvant (same one used in the recently reported malaria vaccine) ...3/n
...Includes this overview of preclinical toxicity studies. (Note, they've also published this study on some preclinical work tandfonline.com/doi/full/10.10…) ...2/n
...The phase 3, #4Humanity trial in the Middle East - here are the blood collections taken across all the countries. (No answer here to the question of whether there were regular tests for Covid-19 in the UAE part of the trial)...3/n
The evidence assessments - but not the WHO decisions - for Sinopharm's Beijing vax & Sinovac's CoronaVac are going up on the WHO website who.int/news-room/even… HT @lutl88@hvasquezhg ...1/n
...Sinopharm Beijing: WHO assessment. 45,000-participant trial in UAE/Bahrain/Egypt/Jordan, doses 21 days apart, efficacy:
- Overall: 78.1% (CI 65-86)
- For people with no previous infection: 80.8% (67-89) (the usual efficacy rate for others)